Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QiShen YiQi Dripping Pills in Chronic Heart Failure
NCT04983043Phase 2Completed
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Jul 2021
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of qishen yiqi dripping pills in heart failure with reduced ejection fraction (HFrEF) (3 arms), sponsored by Tasly Pharmaceutical Group Co., Ltd. Primary endpoint: 6-Minute Walk Test at 12 weeks. Started Jul 2021; status: completed.
02
Drugs
qishen yiqi dripping pills
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT04983043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04983043.